100% Safe customs clearance high quality Rofecoxib CAS 162011-90-7 with Best Price
162011-90-7
Pharmaceutical Grade
99%
shanghai
1kg/bag;25kg/Cardboard Drum
2026-03-02
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceOff-White (Pale Yellow) Crystalline PowderChEBI: A butenolide that is furan-2(5H)-one that is substituted by a phenyl group at position 3 and by a p-(methylsulfonyl)phenyl group at position 4. A selective cyclooxygenase 2 inhibitor, it was used from 1999 to 2004 for the tr atment of ostoarthritis, but was withdrawn following concerns about an associated increased risk of heart attack and stroke.Rofecoxib ts a non-steroidal anti-inflammatory drug (NSAID) launched in Mexico, its first market, f
Rofecoxib is a butenolide that is furan-2(5H)-one substituted by a phenyl group at position 3 and by a p-(methylsulfonyl)phenyl group at position 4. A selective cyclooxygenase 2 inhibitor, it was used from 1999 to 2004 for the treatment of ostoarthritis, but was withdrawn following concerns about an associated increased risk of heart attack and stroke. It has a role as a cyclooxygenase 2 inhibitor, a non-steroidal anti-inflammatory drug and an analgesic. It is a sulfone and a butenolide.|Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2. Cytochrome P450 1A2, Cytochrome P450 3A4, Cytochrome P450 2C9, Cytochrome P450 2C8, and Prostaglandin G/H synthase 1 are known to metabolize rofecoxib. On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.|Rofecoxib is a nonsteroidal antiinflammatory drug (NSAID) that selectively inhibits cyclooxgenase-2 (Cox-2), which was used in the therapy of chronic arthritis and mild-to-moderate musculoskeletal pain. Rofecoxib was withdrawn in 2004 because of an association with an increase in cardiovascular events with its long term use. Rofecoxib had also been linked transient serum aminotransferase elevations during therapy and to rare instances of idiosyncratic drug induced liver disease.|Rofecoxib is a synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties. Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)Basic Info-
Product Name:
Rofecoxib
Other Name:2(5H)-Furanone,4-[4-(methylsulfonyl)phenyl]-3-phenyl-;4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone;3-Phenyl-4-[4-(Methylsulfonyl)phenyl]-2(5H)-furanone;MK 0966;Rofecoxib;MK 966;Vioxx;3-(4-Methanesulfonylphenyl)-2-phenyl-2-buten-4-olide;4-[4-(Methanesulfonyl)phenyl]-3-phenyl-5H-furan-2-one;Rhuma-cure;Ceeoxx;Ceoxx;Romacox;186912-82-3;2484980-39-2
CAS No.:162011-90-7
Molecular Formula:C17H14O4S
InChIKeys:InChIKey=RZJQGNCSTQAWON-UHFFFAOYSA-N
Molecular Weight:314.36
Exact Mass:314.36
EC Number:1806241-263-5
UNII:0QTW8Z7MCR
NSC Number:758705|720256
DSSTox ID:DTXSID2023567
NCI Thesaurus Code:C1832
Color/Form:White to off-white to light yellow powder
ATC Code:M - Musculo-skeletal system
HScode:2932209090
Categories:
Characteristics-
PSA:
68.8
XLogP3:2.3
Appearance:white to beige
Density:1.333±0.06 g/cm3(Predicted)
Melting Point:207°C
Boiling Point:577.6±50.0 °C(Predicted)
Flash Point:303.1±30.1 °C
Refractive Index:1.619
Water Solubility:H2O: Insoluble ;DMSO: soluble 5mg/mL, clear (warmed)
Storage Conditions:Refrigerator
Vapor Pressure:3.2X10-9 mm Hg at 25 deg C /Estimated/
Henrys Law Constant:Henry's Law constant = 2.6X10-12 atm-cu m/mole at 25 °C /Estimated/
Experimental Properties:Hydroxyl radical reaction rate constant = 1.3X10-10 cu cm/ molecule-sec at 25 °C /Estimated/
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Location:
XINYUAN DADUHUI PHASE 1, NO.258 TAOYUAN NORTH ROAD, LIANHU DISTRICT, XI 'AN , SHAANXI CHINA
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
30
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
